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Cardiovascular morbidity and mortality in patients with
chronic kidney disease (CKD) is high, and the presence of
CKD worsens outcomes of cardiovascular disease (CVD). CKD
is associated with specific risk factors. Emerging evidence
indicates that the pathology and manifestation of CVD
differ in the presence of CKD. During a clinical update
conference convened by the Kidney Disease: Improving
Global Outcomes (KDIGO), an international group of experts
defined the current state of knowledge and the implications
for patient care in important topic areas, including coronary
artery disease and myocardial infarction, congestive heart
failure, cerebrovascular disease, atrial fibrillation, peripheral
arterial disease, and sudden cardiac death. Although optimal
strategies for prevention, diagnosis, and management of
these complications likely should be modified in the presence
of CKD, the evidence base for decision making is limited.
Trials targeting CVD in patients with CKD have a large
potential to improve outcomes.
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In October 2010, the KDIGO (Kidney Disease: Improving
Global Outcomes) convened a Clinical Update Conference in
London, United Kingdom, titled ‘Cardiovascular Disease in
CKD: What is it and what can we do about it?’ The objective
was to define the current state of knowledge about
cardiovascular disease (CVD) in patients with chronic kidney
disease (CKD) stages 1–5 (see Table 1 for terminology).
Topics included epidemiology, pathophysiology, diagnosis,
prevention, and treatment, focusing on areas of clinical
relevance: (1) coronary artery disease (CAD) and myocardial
infarction (MI); (2) congestive heart failure (CHF); (3)
cerebrovascular disease, stroke, atrial fibrillation, peripheral
arterial disease (PAD); and (4) sudden cardiac death (SCD).
A total of 80 international experts in these areas attended,
including nephrologists, cardiologists, neurologists, and
representatives of other disciplines. This is a report on con-
ference proceedings and recommendations; it is not intended
as a critical review of available literature. Conference details
are posted on the KDIGO website, http://www.kdigo.org/
meetings_events/Cardiovascular_Disease_in_Chronic_Kidney_
Disease.php. Growing evidence suggests that CKD is an
important, independent risk factor for CVD. Many patients
with CKD die prematurely before or after beginning dialysis.
Reasons for these adverse associations are not well under-
stood and are thus the subject of controversy. Whether CVD
events differ in patients with and without CKD is poorly
defined. Similarly, whether differences in CVD in CKD
patients suggest preventative or therapeutic strategies unique
to this population is unclear.
CAD AND MI
Epidemiology and pathophysiology
The incidence and severity of obstructive CAD increases as
glomerular filtration rate (GFR) declines.1,2 CAD shows a
pattern of diffuse multi-vessel involvement with coronary
calcification;2,3 small angiographic studies suggest that this
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incidence exceeds 50% in unselected CKD 5D patients.4–7
Among patients with CAD, concomitant CKD portends a
worse prognosis. Cardiovascular morbidity and mortality are
inversely and independently associated with kidney function,
particularly at estimated GFRo15 ml/min per 1.73 m2.8–15
Although the absolute incidence and mortality rate of MI is
clearly elevated in advanced CKD,16 standard cardiovascular
risk factors are common in the setting of CKD, and the
degree to which CKD is independently associated with the
risk of initial MI is not well defined. Standard cardiovascular
risk factors are common in CKD, but do not fully explain
the high incidence of cardiovascular events or increased
mortality rates;17–19 their association with cardiovascular
outcomes is attenuated or even reversed at the most advanced
CKD stages.20 Inflammation and oxidative stress have been
linked to the pathogenesis of plaque formation and plaque
rupture;21 both are associated with worse cardiovascular
outcomes.7,22–24 The role of mineralocorticoid excess in the
development of cardiovascular complications is increasingly
recognized.25 Recent studies have implicated disordered
mineral and bone metabolism in the pathogenesis of
coronary disease and CVD in CKD patients.26–28
Diagnosis
Although early detection of coronary plaque may permit
risk factor modification and pharmacological intervention,
the increased prevalence of CAD among CKD patients
diminishes the negative predictive value of diagnostic studies
in this population. CKD patients are underrepresented in
cohort studies evaluating the diagnostic sensitivities and
specificities of non-invasive tests. Exercise electrocardiogra-
phy is limited by lack of specificity of the ST-segment
response and by inability of many CKD patients to exercise
to a diagnostic workload.29,30 The risks of contrast agents
limit the use of perfusion magnetic resonance imaging and
computed tomography coronary angiography, and the latter
is compromised by a high prevalence of coronary calcifica-
tion among CKD patients.31 Radionuclide perfusion imaging
is more sensitive but less specific than stress echocardio-
graphy,32 but may be problematic in the setting of elevated
left-ventricular (LV) mass index and frank LV hypertrophy
(LVH) because limited spatial resolution and disturbed
coronary flow reserve may lead to false results.30 The accu-
racy of exercise and of pharmacological myocardial perfusion
imaging is reduced in CKD patients compared with the
general population, and sensitivities and specificities o80%
have been reported.4,29,33 Conversely, stress echocardiography
may be compromised by small LV cavity size in patients
with elevated LV mass index.34,35 Sensitivity and specificity
for pharmacological stress echocardiography is 69–95% and
76–94%, respectively.36,37
Diagnosis of acute coronary syndrome may also be
problematic in CKD. The classic triad of ischemic symptoms,
elevated cardiac biomarkers, and electrocardiographic
changes is frequently absent in CKD patients,38,39 who are
more likely to present with systolic or diastolic dysfunction
causing heart failure symptoms, or with syncope.39 LVH with
a strain pattern may mask diagnostic ST depression.
Conversely, creatine kinase MB isoform and cardiac tropo-
nins (cTns) may be elevated in the absence of true myocardial
necrosis, possibly because of myocardial apoptosis or small
vessel disease.40 This mandates careful attention to trends
over time and reduces the value of single tests, a problem that
may be exacerbated by increased sensitivity of next-genera-
tion troponin assays.
Prevention
The altered relationship of typical risk factors with cardio-
vascular outcomes41–43 and the routine exclusion of patients
with advanced CKD from most clinical trials testing CVD
therapies44,45 engender doubt about the relevance of existing
standards of care to these patients. Evidence of the efficacy
of glycemic or blood pressure (BP) control or lifestyle
modification to reduce cardiovascular events in patients with
advanced CKD remains limited. Strict glycemic control may
not benefit CKD 5D patients.46,47 Randomized data on the
efficacy of specific BP goals in CKD 5D patients are lacking.
The labile nature of BP and the absence of clear associations
between hypertension and adverse cardiovascular outcomes
in CKD 5D48 preclude definitive recommendations about BP
control.49 Lifestyle modifications have not been widely
studied in CKD patients; in a small trial, multifactorial
intervention that included smoking cessation was not
associated with significant cardiovascular benefits.50 Never-
theless, smoking cessation, exercise, dietary salt reduction,
and weight loss are reasonable interventions at all CKD
stages, and control of hypertension to usual goals or lower is
indicated to slow CKD progression in patients with pre-
dialysis CKD.
Data are sparse regarding efficacy of prophylactic aspirin
in advanced CKD. Subgroup analyses of randomized
trials have demonstrated convincing cardiovascular risk
reduction from daily aspirin in individuals with estimated
GFRo45 ml/min per 1.73 m2, including CKD 5D patients,
despite higher incidence of bleeding in CKD patients.51,52
With release of initial results from the SHARP (Study of
Heart and Renal Protection) trial, statins may now be the
best-studied medical therapy in the context of advanced
Table 1 | Glossary of KGIDO chronic kidney disease (CKD)
abbreviations
Abbreviation Definition
CKD All stages of CKD, including dialysis
CKD 1, 2,
3, or 4
Specific stages of CKD
CKD 5 Dialysis- and non-dialysis-dependent CKD stage 5
CKD ND Non-dialysis-dependent CKD
CKD 5D Dialysis-dependent CKD stage 5, including hemodialysis
and peritoneal dialysis; equivalent to end-stage renal
disease
CKD 5HD Hemodialysis
CKD 5PD Peritoneal dialysis
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CKD. Nevertheless, debate continues regarding their appro-
priate role. A subgroup analysis of several randomized
clinical trials suggests benefit in patients with moderate
CKD.53 Conversely, two large trials comparing statins with
placebo in hemodialysis patients did not demonstrate
benefit.54,55 More recently, in the SHARP trial, the combina-
tion of simvastatin and ezetimibe in CKD patients (including
CKD 5D) reduced major atherosclerotic events by 17%, but
did not appear to reduce overall mortality.56 As no significant
harm from statin use was demonstrated in any of the trials,
this reduction in non-fatal events provides a rationale for the
use of statins in CKD patients despite the apparent lack
of efficacy in reducing the risk of death.
Treatment
Randomized data on treatment of acute MI in CKD patients
are sparse, but treatment approaches using aspirin, clopido-
grel, b-blockers, and angiotensin-converting enzyme inhibi-
tors (ACEIs)/ARBs (angiotensin receptor blockers) seem to
have similar benefits in CKD and non-CKD patients.57,58
Several antiplatelet and anticoagulant agents are metabolized
through the kidneys and warrant dose adjustment in CKD
patients, and low-molecular weight heparins and eptifibatide
may not be safe in CKD 5D patients.59
There is little reason to believe that kidney impairment
diminishes the benefits of immediate reperfusion therapy in
acute ST-elevation MI, but there are no randomized trials
of reperfusion therapy in CKD. A recent analysis suggests
that, when immediately available, primary percutaneous
coronary intervention (PCI) should be the treatment of
choice irrespective of CKD status.60
Among patients with non-ST elevation acute coronary
syndrome (unstable angina and non-ST-elevation MI), the
primary decision is between immediate angiography and
a conservative approach. In the general population, an early
invasive strategy reduces post-acute coronary syndrome
morbidity and mortality by 20–30%,61 and guidelines
recommend early angiography in high-risk patients.62 A
recent meta-analysis suggested similar benefits in CKD 3–4
patients,63 but CKD 4 was underrepresented (no300) and
CKD 5D patients were not included. Conversely, a recent
retrospective analysis of all non-ST-elevation MI patients in
Sweden suggested that an early invasive strategy was harmful
for CKD 5 patients.64
There is a paucity of data regarding revascularization in
CKD patients with stable angina. Surgical coronary revascu-
larization is generally recommended for non-CKD patients
with high-risk features such as left-main CAD, and PCI is
typically recommended for symptomatic single- or two-vessel
CAD or when a significant amount of myocardium is at
risk.65,66 No randomized clinical trials compare coronary
revascularization strategies in advanced CKD patients.
A subgroup analysis of the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation)
trial did not find a benefit from PCI compared with medical
therapy in B320 patients with CKD 3–4 and predominantly
anatomically low-risk, multivessel disease.67 The ARTS-1
(Arterial Revascularization Therapies Study) trial found
no significant difference in the primary end point (death,
MI, stroke) between PCI and coronary artery bypass graft
(CABG) surgery in 290 patients with creatinine clearance
o60 ml/min.68 However, the revascularization rate was
markedly lower in the CABG arm.
Observational data consistently show increased risk
of serious operative complications in CKD patients.66–74
Incidence of operative death after CABG is 9–12.2% for CKD
5D patients, and 3- to 7-fold higher in CKD 4–5ND patients
than in non-CKD patients.69–71 PCI may be an alternative,
but may pose the added risk of contrast-induced nephro-
pathy. In a study of CKD 5D patients undergoing first
revascularization, in-hospital mortality was lower with
PCI (4.1 vs 8.6%), but 2-year survival was better with CABG
(56.4 vs 48.4%).72 Similarly, a more recent retrospective study
demonstrated that in CKD 5D, CABG was associated with a
71% reduction in the risk of death compared with PCI.73
Available studies thus provide conflicting evidence on the
relative merits of PCI and CABG in CKD patients. These
studies may also be biased by differential referral of CKD
patients to CABG or PCI. Studies in the drug-eluting stent
era provide conflicting evidence on their benefit in CKD
patients.74,75
Table 2 lists knowledge gaps and research needs.
CONGESTIVE HEART FAILURE
Epidemiology
CKD is associated with increased prevalence of concomitant
CHF, ischemic heart disease, cardiac arrhythmias (most
commonly atrial fibrillation), and valvular calcification.76–78
In observational studies, CHF prevalence increases with
declining kidney function.79 CHF is the leading cardio-
vascular condition in CKD patients,80 with mortality slightly
higher for diastolic than for systolic CHF.81 Terminal events
in CHF are pump failure and sudden arrhythmic death.
Pathophysiology
CKD exposes the heart to three major mechanisms that
facilitate the development of cardiomyopathy and induce
LV failure: pressure overload, volume overload, and CKD-
associated non-hemodynamic factors that alter the myo-
cardium (Figure 1). Pressure overload is largely the result of
long-standing hypertension and vascular stiffness. Increased
LV wall stress (from pressure and volume overload) fuels
changes in the composition and function of the myocardium,
and this process is accentuated by CKD-associated abnor-
malities. CKD progression is accompanied by progressive
LVH and diastolic dysfunction.82 Arterial stiffening may be a
key etiological aspect in CKD leading to CVD.83,84
Beyond hemodynamic factors, inappropriate activation
of the renin–angiotensin system, catalytic iron-dependent
oxidative stress, inflammation, and stimulation of pro-
hypertrophic and profibrogenic factors (cardiotrophin-1,
galectin-3, transforming growth factor-b, fibroblast growth
574 Kidney International (2011) 80, 572–586
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factor-23) may be relevant.85 The bufadienolides (steroid
hormones circulating in the blood and excreted in urine) are
elevated in CKD. They inhibit preferentially the a1 isoform
of Naþ -Kþ -ATPase, resulting in volume expansion and
hypertension.86 Histopathological studies indicate that capil-
lary density is reduced in the hypertrophied myocardium,
and pronounced interstitial fibrosis is a dominant feature of
CKD-associated structural myocardial remodeling.
LV diastolic dysfunction is frequent among CKD patients
and is associated with the risk of CHF and increased
mortality; impaired diastolic function may occur early
in CKD, even without LVH.85 Myocardial fibrosis results
from an imbalance between exaggerated collagen synthesis
and unchanged or depressed collagen degradation. In CKD
patients, it is a major determinant of LV stiffness, increased
LV filling pressure, and disturbances in diastolic filling,
predisposing to development of diastolic dysfunction/
failure.87
In CKD patients, resting LV systolic function is usually
normal or even hyperdynamic, at least in the absence of
Table 2 | Future directions for cardiovascular disease in chronic kidney disease
Condition Knowledge gaps Research needs
CAD, MI Screening may be beneficial, but data are insufficient
to advocate screening asymptomatic patients.
Evidence lacking regarding primary and secondary
treatment of CAD.
Cardiovascular trials have frequently excluded CKD
patients from enrollment.
Clarify the interdependence of CKD with MI, and its relation to demographic
characteristics such as gender.
Clarify the pathophysiological relationship between development of plaque
and subsequent rupture of selected plaques.
Clarify roles of novel risk factors that are potential therapeutic targets.
Broad-based validation of current stress and imaging modalities using
coronary angiography with fractional flow reserve.
Adequately powered CKD-specific clinical trials of aspirin, statins, novel anti-
lipidemic agents, ACEIs, and ARBs.
Define the ideal LDL cholesterol level and the role of newer antiplatelet and
anticoagulant therapies.
Randomized clinical trials comparing early invasive with conservative therapy
post-ACS, and PCI with CABG.
CHF Understanding development and prevention of LVH,
fibrosis, and LV dysfunction (systolic and diastolic).
Benefits of prolonged or quotidian dialysis.
Absence of CKD-specific data on CHF treatment.
Impact of sodium balance (intake, dialysate sodium
concentration).
Evaluate asymptomatic LV dysfunction, examine changes in the kidney and
cardiac function over time, and incorporate kidney- and cardiac-specific
biomarkers.
Clinical studies to investigate innovative monitoring and management
techniques (serial biomarkers, bioimpedance, chronic in vivo monitoring.212
Evaluate effects of CHF-specific risk-modifying and cardio-protective therapies
(ACEIs, ARBs, renin and mineralocorticoid hormone inhibitors.
Investigate speculative treatments (vitamin D analogs/calcimimetics, cytokine-
modulating drugs, iron-related treatments, endothelin receptor blockers,
regenerative therapies).
Stroke High-quality observational data on risk factors,
precipitants, etiological subtypes, causes of death,
and underlying arteropathies.
Risk of carotid artery stenting is undefined.
Few data on treatment of acute stroke.
Randomized clinical trials testing interventions for secondary prevention of
stroke.
Determine safety of intravenous thrombolysis of CKD 5D patients with acute
ischemic stroke.
Atrial
fibrillation
Risks/benefits of anticoagulation with warfarin for
stroke prevention.
Efficacy, safety of dabigatran in stage 4 CKD.
Uncertainty regarding validity of the 2005 KDOQI
guidelines regarding anticoagulation in dialysis
patients with atrial fibrillation.
Randomized clinical trials of warfarin and novel anticoagulants for stroke
prevention in CKD 4–5D patients with atrial fibrillation.
Interventions to prevent atrial fibrillation: radio frequency ablation,
percutaneous closure of the left-atrial appendage, surgery.
PAD Few high-quality observational data on risk factors.
Role of ankle-brachial index vs other diagnostic
techniques.
Prospective data on non-surgical therapies.
Data regarding percutaneous vs surgical
revascularization.
Determine prevalence of preventive foot care.
Assess regional differences in practice patterns.
Generate management guidelines.
Assess amputation frequency in programs that do and do not perform
preventive foot care.
Study bacteriology of diabetic patient feet.
SCD Standard risk factors derived from the general
population may not apply.
Few autopsy data.
Dialysis patients excluded from primary and
secondary prevention trials.
Disease-specific, large-scale prospective cohort studies for risk stratification.
Study heterogeneous CKD populations at all stages using all available risk-
stratification techniques.
Remove barriers preventing data linkage to allow for population-wide cohort
and case–control studies.
Randomized trials assessing the spectrum of interventions: b-blockers (such as
carvedilol), ICDs, sympathetic ablation.
Incorporate SCD as specific outcome in registry and clinical trial data.
Investigate the potential role of sleep apnea in SCD.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft surgery;
CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; ICD, implantable cardioverter-defibrillator; KDOQI, Kidney Disease Outcomes Quality
Initiative; LDL, low-density lipoprotein; LV, left ventricular; LVH, LV hypertrophy; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary
intervention; SCD, sudden cardiac death.
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ischemic heart disease or severe hemodynamic stress.88
Hemodialysis is associated with repetitive hemodynamic
instability and subsequent myocardial ischemia (perhaps
due to microvascular dysfunction), resulting in prolonged
LV systolic dysfunction (‘myocardial stunning’) and adverse
outcome.89
Diagnosis
The clinical syndrome of CHF in CKD, heralded by effort
intolerance, fatigue, and edema, is difficult to distinguish
from volume overload. Echocardiography (including tissue
Doppler imaging) has a key role in diagnosing LVH, diastolic
and systolic LV dysfunction, and global assessment of cardio-
vascular prognosis. Despite issues of cost and availability,
performing an echocardiogram is reasonable in each CKD
patient with cardiac symptoms, new clinical events, or
treatments likely to affect LV function.90 The Current Kidney
Disease Outcomes Quality Initiative (KDOQI) guidelines
recommend echocardiograms for all CKD 5D patients 1–3
months after renal replacement therapy initiation and in
subsequent 3-year intervals, regardless of symptoms.91
Follow-up with serial examinations at closer intervals of
12–18 months may increase prognostic value.92,93 Less clear
is the usefulness of B-type natriuretic peptides (BNP and
NT-proBNP) in the diagnosis and management of CHF; the
concentration of these peptides is influenced by kidney
function and by CHF severity.94,95
The cTns T and I, biomarkers of cardiomyocyte damage,
accumulate in CHF. Although the clinical significance of
increased cTn concentrations in CKD patients with CHF is
unclear,94 they are strong predictors of all-cause mortality in
CKD 5D, and the US FDA (Food and Drug Administration)
approved cTnT for risk stratification in CKD 5D patients.96,97
Novel cardiac and renal biomarkers include neutrophil
gelatinase-associated lipocalin, kidney injury molecule 1,
interleukin-18, galectin-3, mid-regional pro-adrenomedullin,
catalytic iron, and markers of oxidative stress.94 For all these
markers, the critical issue is independence of GFR. A recent
review scaled the following in order of decreasing effect size:
tumor necrosis factor-a, hematocrit, interleukin-6, cTn T,
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Figure 1 |Cardio–renal syndrome pathophysiology. ADH, antidiuretic hormone; ANP, atrial natriuretic peptide; BNP, B-type natriuretic
peptide; CKD, chronic kidney disease; DM, diabetes mellitus; EPO, erythropoietin; HTN, hypertension; IL-1, interleukin-1; KIM-1, kidney injury
molecule-1; LV, left ventricular; N-GAL, neutrophil gelatinase-associated lipocalin; NSAID, non-steroidal anti-inflammatory drug;
OSAS, obstructive sleep apnea syndrome; PTH, parathyroid hormone; SNS, sympathetic nervous system; TNF-a, tumor necrosis factor-a;
TZD, thiazolidinediones; VSMC, vascular smooth muscle cell.
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Kt/V(urea), prealbumin, urea reduction ratio, serum albumin,
and C-reactive protein.98 Only troponin T has strong biological
plausibility for a link to myocardial disease; the others appear
to represent chronic illness, inflammation, and malnutrition.
Prevention and treatment
Prevention relies on BP and volume control and modification of
usual risk factors for CHF and CKD progression. Treatment of
CHF in CKD patients using the European Society of Cardiology
Guidelines is reasonable;99 however, these therapeutic strategies
are not based on strong evidence, as CKD patients are not
adequately represented in randomized controlled trials in CHF.
Dietary salt restriction should be a mainstay of clinical
counseling. With regard to pharmacological treatment,
several considerations are appropriate.100 CHF patients with
kidney dysfunction often retain excessive salt and water and
require more intensive diuretic treatment than do CHF
patients with normal kidney function. Aldosterone antago-
nists should be used with caution as they may cause signi-
ficant hyperkalemia. Despite strong evidence from rando-
mized clinical trials that suggests that treatment with ACEIs
and ARBs reduces cardiovascular morbidity and mortality in
CHF, there is little equivalent evidence for CKD patients.
Randomized clinical trials of CHF management with ACEIs,
ARBs, new direct renin inhibitors, and mineralocorticoid
receptor blockers (with or without potassium-binding resins)
are required for CKD patients. Specialist supervision is
recommended for patients with GFR levels belowB30 ml/min
per 1.73 m2. One small randomized trial supports the com-
bined use of ACEIþARBs in the treatment of CHF in CKD
5D patients.101 Recent data strongly support the use of
bisoprolol102 or carvedilol103 in CKD patients with CHF.
Other potentially useful management strategies include
correcting anemia and minimizing vascular calcification.100
Anemia correction, aiming for hemoglobin levels 410 g/dl, has
been shown to reduce LVH in CKD patients,104 but total
correction does not further improve LV geometry or cardio-
vascular outcome.105,106 Erythropoiesis-stimulating agents and/
or intravenous iron107 may improve exercise tolerance but are
without survival benefit.108,109 Control of calcium and phos-
phate concentrations is instrumental in minimizing vessel
calcification. Concern about calcification due to calcium-
containing phosphate binders is increasing.110,111 Therefore,
the use of non-calcium-containing phosphate binders may be
advantageous,112 although data are insufficient to establish the
comparative superiority of these agents over calcium-containing
phosphate binders for cardiovascular end points in CKD.113
Achieving adequate vitamin D status and avoiding excessively
high or low parathyroid hormone concentrations (oversuppres-
sion) are reasonable treatment goals, although their efficacy has
not been demonstrated.
For CKD 5D patients with CHF, adequate ultrafiltration
should be coupled with dietary sodium restriction and lower
dialysate sodium concentrations; more frequent or longer
dialysis sessions may be beneficial.114,115 High-flow fistulae or
grafts may cause high cardiac output states.116
Evidence for management of acute CHF in CKD is limited.
Inotropic therapy (dobutamine, milrinone, levosimendan)
may be considered in patients with worsening renal function
secondary to the fall in cardiac output; however, routine use
of inotropes or other adrenergic-stimulating agents for acute
decompensated CHF is not indicated in CKD patients.117
Ultrafiltration may be useful in refractory congestion.
Table 2 lists knowledge gaps and research needs.
CVD AND STROKE, ATRIAL FIBRILLATION, PERIPHERAL
ARTERIAL DISEASE
Stroke
CKD 3–4 is an independent risk factor for ischemic and
hemorrhagic stroke, with a relative risk of B1.4 (ref. 118).
The relative risk of stroke in CKD 5D patients was estimated
to be 5–10 times that of the age-matched general popula-
tion119 with an overall stroke rate of B4% per year.
Ischemic stroke is caused by several distinct arteriopathies;
few studies using modern imaging techniques and classifica-
tion paradigms have assessed etiological subtypes in CKD
patients. The best recent descriptive data in CKD 5D patients
come from the prospective CHOICE (Choices for Healthy
Outcomes in Caring for ESRD) study, involving 1041
incident US CKD 5D patients (74% receiving hemodialy-
sis).120 The observed stroke rate was B4.2% per year. Most
(87%) strokes were ischemic, and the distribution of etio-
logical subtypes was similar to the distribution in registries
of CKD ND patients. Independent predictors of higher risk
were age and diabetes. African-American race was asso-
ciated with lower risk. About one-third of strokes occurred
during or shortly after hemodialysis treatment.120,121 The
stroke mortality rate was nearly three times higher (35%)
than that for non-end-stage renal disease patients. High
mortality rates were also reported in three randomized trials
in which 43,55 38,54 and 36%122 of all strokes were fatal,
apparently reflecting ischemic stroke. The high fatality rate
could reflect systematic underdetection of minor strokes in
CKD 5D patients or withdrawal of dialysis when stroke
occurs. Less is known about stroke rates and stroke subtypes
in end-stage renal disease patients undergoing peritoneal
dialysis, but available data support similar rates.120,123 CKD 4
seems to be an independent risk factor for fatal stroke.124
Evidence-based secondary prevention of non-cardioembolic
ischemic stroke includes BP lowering, antiplatelet agents,
statin therapy, and, in the presence of ipsilateral high-grade
carotid stenosis, carotid endarterectomy. BP lowering with
ACEIs and thiazide diuretic reduced stroke recurrence
in patients with CKD 3–4.125 Optimal BP management in
CKD 5HD patients with prior stroke has not been defined.
Exploratory analyses of randomized trials show that low-dose
aspirin for primary prevention of stroke in hypertensive
CKD 3–4 patients51 and antiplatelet therapy for prevention
of major vascular events are effective in CKD 5HD.52 Efficacy
of antiplatelet prophylaxis likely extends to secondary
stroke prevention in CKD patients, but no randomized trial
data are available. Statin therapy was not efficacious for
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stroke prevention in CKD 5D patients,54,55 but results of the
SHARP trial indicate efficacy of statins for prevention of
atherosclerotic events (including ischemic stroke) in CKD
patients.56
A subgroup analysis of the NASCET (North American
Symptomatic Carotid Endarterectomy) trial demonstrated
absolute benefit of carotid endarterectomy for CKD 3
patients with recent cerebral ischemia and high-grade
ipsilateral carotid stenosis.126 Carotid artery stenting is more
frequently performed recently, and the benefits and risks of
carotid artery endarterectomy have been defined by large
randomized trials.127,128 Although results have engendered
controversy, the trials are generally interpreted as favoring
endarterectomy except in special circumstances.128 Because
CKD, particularly CKD 5D, patients’ carotid arteries are
unduly calcified and stiff, complications of stenting may
be increased. The risk of perioperative complications of
carotid endarterectomy also seems to be higher for CKD
patients.129,130 Both procedures require administration
of substantial amounts of iodinated contrast for cerebral
arteriography (although many surgeons perform endarte-
rectomy based on non-invasive imaging). The benefit vs risk
of these procedures compared with medical therapy has not
been defined for CKD 5D patients.
Intravenous thrombolysis with tissue plasminogen
activator is of net benefit for patients with ischemic stroke
when given within 4.5 h of symptom onset, with intracranial
bleeding as the major complication. In small studies,
intracranial hemorrhage was not increased in patients with
CKD stages 3–4 (refs. 131,132). However, CKD may be an
independent predictor of poor neurological outcome.131
Many acute strokes occur in CKD 5D patients. The 2005
KDOQI guidelines on CVD in dialysis patients recommend
considering thrombolysis on an individual basis.91 The safety
of intravenous thrombolysis has not been defined in CKD
5HD patients with acute ischemic stroke. Heparin adminis-
tered during dialysis is often problematic in this situation
because recent heparin use with prolonged activated partial
thromboplastin time is generally considered a contraindica-
tion to intravenous tissue plasminogen activator.
The 2005 KDOQI guidelines state that all CKD 5D
patients should follow the AHA (American Heart Associa-
tion) guidelines for prevention, screening, evaluation, and
treatment of stroke, with minor caveats.91 The paucity of
new data precludes modification of most previous KDOQI
recommendations.
Atrial fibrillation
Atrial fibrillation is the most common cardiac rhythm distur-
bance in CKD patients; prevalence among dialysis patients is
15–20%, and it is associated with increased incidence of
stroke.133–135 The mechanism of stroke associated with atrial
fibrillation is embolization of left atrial appendage thrombus.
Multiple randomized clinical trials of anticoagulation with
the vitamin K antagonist warfarin in the general population
have shown a marked reduction in stroke with warfarin
compared with placebo or aspirin.136 Thus, the American
College of Cardilogy/AHA/European Society of Cardiology
guidelines recommend anticoagulation with warfarin for
primary and secondary prevention of stroke in patients with
atrial fibrillation.137 Extrapolating these data to CKD 5D
patients, the 2005 KDOQI guidelines recommend anti-
coagulation in non-valvular atrial fibrillation with careful
monitoring due to increased risk for bleeding.91 However,
randomized controlled trials of antithrombotic therapy for
stroke in atrial fibrillation patients excluded CKD 5D patients.
The clinical conundrum balances reduced risk of stroke
with warfarin with increased risk of anticoagulant-associated
bleeding, vascular calcification, and calciphylaxis.138 Multi-
variate analyses of placebo- and aspirin-assigned patients
from randomized clinical trials identified several risk factors
that have been incorporated into stroke risk-stratification
schemes. The most common is the CHADS2 risk score,139
which assigns one point each for CHF (moderate to severe
decreased LV systolic performance), hypertension, age older
than 75 years, and diabetes, and two points for previous
stroke. Patients with a CHADS2 score greater than one are
generally considered to be at sufficient risk for stroke to
warrant warfarin treatment (target international normalized
ratio range of 2–3). Because CKD 5D patients were not
included in randomized controlled trials of warfarin, they
were also not included in derivation of this or of most other
stroke risk-stratification schemes. One large retrospective
study of hemodialysis patients with atrial fibrillation found
that increasing age, CHF, and systolic BP correlated with
stroke risk.140 Multivariate analysis of another study reported
that previous stroke, diabetes, and advancing age indepen-
dently predicted hospitalization for stroke, but hypertension
and CHF did not.134 These and a third study reported that
the CHADS2 scheme successfully stratified stroke risk in
CKD 5D patients with atrial fibrillation, but the contribution
of each component appeared to differ.134,140,141 How reliably
the CHADS2 and other stroke risk-stratification schemes
apply to CKD 5D patients with atrial fibrillation remains
unclear.
It is uncertain how schemes designed to estimate bleeding
risk during warfarin anticoagulation apply to CKD patients,
and particularly to hemodialysis patients.142
Risk stratification for hemorrhage has also been proposed;
two schemes were derived from databases that included atrial
fibrillation patients with CKD.143,144 Both identified CKD as
a risk factor, but how many CKD 5D patients were included
is unclear. CKD 5HD patients have abnormal platelet
function and are subjected to therapeutic heparin three
times a week during dialysis. Excessive bleeding has been
noted in patients administered warfarin in therapeutic
doses.145 The clinical dilemma is that stroke risk increases
with declining kidney function,135 but bleeding risk increases
during warfarin anticoagulation.
Retrospective analyses of large dialysis databases raise
concerns regarding the efficacy of warfarin anticoagulation in
CKD 5HD patients with atrial fibrillation.134,140,146 Studies
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from a national network of incident dialysis patients identi-
fied warfarin use with increased risk of stroke and overall
mortality.140,146 The increased risk of stroke showed a ‘dose
effect,’ with higher international normalized ratios associated
with increased, not decreased, risk.140 Another study from
the DOPPS (Dialysis Outcomes and Practice Patterns Study)
database reported increased stroke hazard ratios for patients
receiving warfarin,134 and that warfarin use in patients aged
older than 75 years was associated with higher stroke risk
(perhaps due to hemorrhagic stroke, but this could not be
determined). These observations prompted reconsideration
of the value of warfarin for stroke prevention in CKD 5D
patients with atrial fibrillation. Weighing the available
evidence, the benefit of warfarin anticoagulation for primary
prevention of stroke in CKD 5D patients is questionable.
The number of patients with atrial fibrillation is projected
to double by the middle of this century,147 stimulating
development of new oral anticoagulants and non-pharma-
cological methods to prevent stroke in atrial fibrillation.148,149
Recently, the US FDA approved the oral direct thrombin
inhibitor dabigatran (150 mg twice daily) for stroke preven-
tion in atrial fibrillation, including CKD 3 patients.150
Dabigatran trough levels correlate with efficacy for stroke
prevention and are altered in CKD patients because 80–85%
of dabigatran is excreted unchanged by the kidney. The
superior efficacy and comparable safety of dabigatran
compared with warfarin was demonstrated in a subgroup
of 3505 participants with estimated creatinine clearanceX30
to p50 ml/min per 1.73 m2 in the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trial.151,152 The 2.8% per year stroke rate among patients
assigned to warfarin was reduced to 1.5% per year (Po0.01)
with dabigatran 150 mg twice daily in CKD 3 patients. The
FDA also approved a reduced dose of dabigatran (75 mg
twice daily) for CKD 4 patients based on pharmacokinetic
and pharmacodynamic studies.153
Therefore, until new data become available, and in
contrast to the previous KDOQI recommendation 9.1,91
routine anticoagulation of CKD 5D patients with atrial
fibrillation for primary prevention of stroke is not indicated,
whereas previous KDOQI recommendations for secondary
prevention and careful monitoring154 of all dialysis patients
receiving anticoagulation remain valid.
Peripheral arterial disease
PAD is common in CKD patients. Among adults aged 440
years with estimated GFRo60 ml/min per 1.73 m2, National
Health and Nutrition Examination Survey data from 1999
to 2000 report prevalence of 24%.155 The Chronic Renal
Insufficiency Cohort study data show PAD in 7% of adult
CKD ND patients;156 prevalence in CKD 5D patients is
17–48%.157,158 CKD is an independent risk factor for PAD
events.159
Higher rates of PAD among CKD patients are attributed
to greater prevalence of traditional risk factors, such as
diabetes, hypertension, dyslipidemia, advanced age, and
‘renal-specific factors.’ A cross-sectional analysis of the
USRDS (United States Renal Data System) data identified
traditional (such as age, male sex, diabetes, smoking) and
kidney-specific risk factors (dialysis duration, low Kt/V,
hypoalbuminemia, low parathyroid hormone) as associated
with PAD.160 Hyperphosphatemia, inflammation, and mal-
nutrition have been associated with PAD in CKD 5D.161–163
Screening for PAD is recommended for adults in the
general population based on age and number of risk
factors.137 For CKD 5D patients, the 2005 KDOQI guidelines
recommend screening (including physical examination with
assessment of arterial pulse and skin integrity) at the time of
dialysis initiation. However, screening guidelines are proble-
matic for clinicians because of the lack of clarity regarding
diagnostic testing and optimal therapies for PAD in CKD.
The ankle–brachial index is widely considered the standard
diagnostic tool for PAD, with o0.9 generally considered the
diagnostic value. Greater prevalence of calcified vessels in
CKD patients raises concerns regarding the utility of this test
in these patients and suggests consideration of alternate tests,
such as toe–brachial index and pulse volume recording.
Limited data on these measurements in CKD 5D patients
demonstrate an association with future cardiovascular events
and amputations.164
Evidence-based medical therapies for PAD in CKD
patients are lacking. Smoking cessation is mandatory. Aspirin
may be beneficial for prevention of cardiovascular events.
Clopidogrel has not been studied in CKD patients with PAD.
Antiplatelet agents carry the risk of bleeding, which is of
particular concern because CKD patients have inherently
higher risks of bleeding associated with renal disease and
heparin use with hemodialysis. Prospective studies regarding
other medical therapies, such as statins, renin–angiotensin
aldosterone system blockade, and exercise therapy, are
required. Cilostazol, a phosphodiesterase inhibitor that
blocks platelet aggregation and functions as a vasodilator, is
also commonly used in PAD. It is approved for symptomatic
management of claudication. A retrospective analysis of its
impact in reducing restenosis among CKD 5HD patients with
PAD who underwent percutaneous transluminal angioplasty
found an association between cilostazol use and 5-year event-
free survival.165
For patients with advanced PAD, particularly those with
critical limb ischemia, revascularization or amputation is
often required. Critical limb ischemia is defined by lower-
extremity ischemic rest pain, ulceration, or gangrene.
No randomized studies evaluating percutaneous vs surgical
revascularization techniques have been conducted in CKD
patients with PAD. Percutaneous methods are preferred,
but outcomes are worse among patients with higher rates
of repeat percutaneous angioplasty, subsequent surgical
revascularization, or limb loss and death.166 In another retro-
spective analysis, CKD 5D patients who underwent percuta-
neous compared with surgical revascularization experienced
higher limb salvage rates.167 Perioperative morbidity and
mortality are high among CKD patients undergoing these
Kidney International (2011) 80, 572–586 579
CA Herzog et al.: CVD in CKD meet ing repor t
procedures. Surgical revascularization is often complicated by
perioperative mortality, prolonged hospitalization, and limb
loss in dialysis patients.167–169 Diabetes, advanced age, and
African-American or American-Indian race/ethnicity are also
associated with greater risk for amputation in this popula-
tion.170,171 Optimal management of CKD patients with critical
limb ischemia is unclear. Rates of complications, including
subsequent amputation and perioperative and 1-year mortal-
ity, are higher for PAD therapies in CKD patients.167,172,173
Preventive strategies may be key for reducing PAD-
associated morbidity, particularly for decreasing amputation
rates. Diabetes is the leading cause of CKD in the United
States. Diabetic foot ulcers and neuropathy increase the risk
of amputations. Small, single-center studies have shown
preventive foot care to be beneficial in reducing amputation
rates in CKD 5D patients with diabetes.174
Table 2 lists knowledge gaps and research needs.
SUDDEN CARDIAC DEATH
Epidemiology
SCD is generally defined as sudden, unexpected death within
an hour of symptom onset, or unwitnessed, unexpected
death without obvious non-cardiac cause in patients known
to be well within the past 24 h.175,176 In CKD 5D patients, this
definition is problematic. Determining the unexpectedness of
death is vexing in patients with a high burden of comorbidity
who spend a disproportionate amount of time in health-care
facilities. CKD 5D patient deaths are frequently unobserved,
and the exact timing is unknown. Many possible non-cardiac
causes (for example cerebrovascular) may contribute to
sudden death in CKD 5D patients, and their relative
contribution is unknown. However, commonly accepted
definitions of SCD should be adopted to facilitate commu-
nication between disciplines and interpretation of pre-
existing literature. Some circumstances unique to CKD 5D
patients may require special consideration. For instance,
sudden death occurring in the setting of missed hemodialysis
treatment should not be considered SCD.
SCD accounts for about one-fourth of dialysis patient
deaths, with an annual rate of 5.5%.177–179 Survival of CKD
5D patients after sudden cardiac arrest is universally poor,
with a 6-month survival of 3–11%.180–183 The cause of death
derived from registry data may be prone to misclassification
because of the lack of a precise SCD definition; however,
findings from randomized clinical trials (HEMO, 4D) and
prospective CKD 5HD (CHOICE) and CKD 5PD cohorts
are remarkably consistent regarding the relative contribution
of SCD to all-cause mortality (22–26%) in dialysis
patients.54,184–187 Further studies in two areas are warranted.
First, little is known about regional differences in SCD
epidemiology. Preliminary evidence suggests that SCD rates
may vary in different populations; for example, reported
rates are substantially lower in Japanese patients. Second,
although available data do not suggest a significant difference
between hemodialysis and peritoneal dialysis patients, less
is known about comparative SCD rates in patients using
non-conventional hemodialytic techniques such as frequent
and nocturnal hemodialysis.
The relationship between less severe CKD stages and SCD
risk has recently been explored. Secondary analyses of
patients with moderate CKD enrolled in the MADIT-II
(Second Multicenter Automated Defibrillator Implantation)
and the COMPANION (Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart Failure) trials have
found an incremental risk of SCD with decreasing baseline
GFR.188,189 Inverse linear relationships between kidney
function and SCD risk have been observed in a large cohort
with CKD and significant CAD,190 postmenopausal women
with CAD,191 and elderly individuals without clinically
significant cardiac disease.192 In one observational study of
19, 440 patients, estimated GFR was independently associated
with sudden death (hazard ratio 1.11 per 10 ml/min decline
in estimated GFR).190 In these studies, the increased risk
of SCD associated with CKD could not be accounted for by
the degree of measured cardiac or other comorbidities.
Pathophysiology
The association between CKD 5D and SCD is multifactorial
and complex, likely involving vulnerable myocardial sub-
strate and superimposed transient triggers. Both are abun-
dant in the dialysis population. For example, CAD is
prevalent among CKD patients, producing structural heart
disease (ischemic cardiomyopathy with decreased systolic
function) and a source of triggering events (acute myocardial
ischemia) from which terminal arrhythmias arise.193 CAD is
the underlying substrate in most SCD in non-CKD
patients,193 and recognized risk factors for CAD identified
in the general population are prevalent among CKD patients.
However, the pathophysiology of CAD as the main deter-
minant of SCD risk is problematic among CKD patients.
Evidence suggests that CAD-related risks are insufficient to
explain the markedly increased risk of SCD among CKD
patients. In CKD ND patients, SCD risk associated with
diminished GFR cannot be accounted for by severity of CAD,
CHF, diabetes, or decreased use of cardiovascular medica-
tions.190 In clinical trials, only 9% of deaths were directly
attributable to CAD, whereas SCD accounted for 26%.54
Recognized risk factors such as LV systolic dysfunction are
present in only a minority of CKD 5D patients, but LVH is
endemic.194,195 The degree to which unique dialysis-specific
complications (such as hyperkalemia) and other non-cardiac
mechanisms contribute to the overall sudden death rate is
unknown, and few autopsy data are available. A small
autopsy series of Japanese CKD 5D patients found stroke to
be the most frequent cause of sudden death (26%), followed
by cardiac disease (19%) and infectious disease (17%).196
Obtaining autopsy data is difficult, but additional studies
using postmortem information would be illuminating.
A related issue is characterizing the primary arrhyth-
mias responsible for sudden death in CKD patients. In the
general population, SCD may be due to several catastrophic
events and sustained ventricular tachycardia and ventricular
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fibrillation constitute about half the cases.197 Whether the
same pattern holds true among CKD 5D patients is unclear,
given the differences in underlying cardiac disease patterns.
Small retrospective studies of presenting arrhythmias in CKD
5D patients with SCD report a wide range of ventricular
arrhythmias (19–72%).181,197–199 Unique metabolic derange-
ments and other non-cardiac events may cause terminal
arrhythmias beyond ventricular tachycardia and ventricular
fibrillation. Characterizing SCD arrhythmias in CKD 5D
patients is important, because non-ventricular arrhythmias
would not be expected to respond to traditional resuscitative
measures involving defibrillation.200 Implantable loop recor-
ders used to identify terminal arrhythmias could prove
useful, but a coordinated effort would be necessary given low
enrollment rates anticipated in such studies.
Prevention
Preventive strategies for SCD in CKD 5D patients should be
a major public health concern. Attempts to evaluate the
efficacy of preventive strategies in CKD patients rely on
reasonable risk-stratification data. This is extremely challen-
ging, as SCD is a generic term encompassing widely disparate
events, the risk factors of which likely also vary widely.
Diminished GFR by itself should be considered a significant
SCD risk factor.188 CKD 5D confers additional risk; one
study suggested that SCD risk doubles in CKD 5 patients
with dialysis initiation.190 Most studies of SCD risk factors in
dialysis patients focus on retrospective and small observa-
tional prospective cohorts, and are limited by small sample
size, inherent limitations in the adjudication of end points,
and failure to examine a wide range of candidate variables.
An important and consistent observation is increased SCD
occurrence in CKD 5HD patients on the first hemodialysis
day following the long intradialytic period, suggesting that
fluid and electrolyte accumulation and rapid shifts during
hemodialysis may be important triggering factors.198,201
Exposure to low-potassium and calcium dialysate, volume
removal on dialysis, and pre-dialysis hyperkalemia and
hypokalemia have been consistently associated with increased
risk of intradialytic SCD.181,186,202 Obstructive sleep apnea
has been associated with arrhythmias in the general
population, and disordered nocturnal breathing is highly
prevalent among CKD 5D patients.203 Although evidence of a
direct link to SCD is lacking, nocturnal hypoxemia in CKD
5D patients has been associated with increased cardiovascular
events.204 Measures of structural heart disease have been
variably associated with increased SCD risk; one small study
suggested that change in the LV mass index is the most
potent predictor of SCD, and another found no association
between LVH and SCD risk.186,205 The high prevalence of
LVH in CKD 5D patients limits its utility in SCD risk
stratification. Ejection fraction p35%, regardless of etiology,
identifies a subgroup of CHF patients with high risk of
sudden death due to arrhythmia, and even milder degrees of
LV dysfunction may be associated with increased event rates
in peritoneal dialysis patients.187
Other non-invasive cardiac markers, including ambient
ventricular ectopy, heart rate variability, QT dispersion, baro-
reflex sensitivity, and T-wave alternans, have been insuffi-
ciently studied in this population to be of clinical utility.
Serum biomarkers, particularly cTnT, have been associated
with all-cause mortality and SCD and may serve as markers
for cardiac apoptosis and CHF. Other biomarkers asso-
ciated with SCD among CKD 5D patients include markers
of inflammation (interleukin-6,186 C-reactive protein,186 and
adiponectin206) and nutrition (serum albumin,186 pre-
dialysis serum creatinine202), but these have not been
validated across cohorts. Multinational observational cohorts
including diverse populations of CKD ND and CKD 5D
patients and examining a broad spectrum of potential risk
factors and risk-stratification techniques are desirable.
The major question facing risk-stratification studies is
what to do with results. Avoiding rapid fluid and electrolyte
shifts and low-potassium dialysate in hemodialysis is
supported by observational data, but controlled trials should
be performed to determine the potential benefit of inten-
sive dialytic management with dialysate and ultrafiltration
profiling to improve tolerance of the hemodialysis procedure.
Whether frequent or long, slow hemodialysis or other
modifications can improve tolerance and help prevent SCD
remains to be seen. Otherwise, few effective therapies are
available to prevent SCD in CKD 5D patients. b-Adrenergic
blockers improved survival and decreased SCD risk in a study
of CKD 5D patients with dilated cardiomyopathy, but more
work in this promising area is required.103 There are no data
on the prevention of SCD using anti-arrhythmic therapy, and
such an approach is unlikely to prove beneficial in CKD 5D
patients. A recent study reported that use of digoxin was
associated with increased mortality in CKD 5HD patients.207
Implantable cardioverter-defibrillators (ICDs), a highly
effective but expensive technology with a proven track record
in CHF patients, have been inadequately studied. Although
4% of all ICD implants in the United States are in CKD 5D
patients, no prospective trial data assess their utility. The
USRDS reports median survival of only 18 months in CKD
5D patients receiving ICDs for primary prevention indica-
tions, well below survival in non-dialysis ICD recipients.179
Observational data suggest modestly improved survival of
CKD 5D cardiac arrest survivors receiving ICDs for secondary
prevention indications.208,209 Complications following device
implantation increase fivefold in CKD 5D patients and short-
term post-implant mortality fourfold.210,211 Whether wear-
able defibrillators or leadless subcutaneous devices can impact
survival while reducing complication rates is unknown.
Table 2 lists knowledge gaps and research needs.
CONCLUSIONS
Data that have become available in recent years generally
reinforce the importance of CVD in determining quality of
life and prognosis of CKD patients. Increasing evidence
demonstrates that pathology, manifestations, and complications
of CVD differ in the presence of CKD. Thus, the risk–benefit
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relationship of management strategies evaluated in the
general population may differ significantly in patients with
CKD. The number of trials that specifically address CVD in
CKD patients, or that enroll CKD patients, remains small;
however, increasing awareness may stimulate future trials.
When results of needed studies of atrial fibrillation, coronary
revascularization, SCD, and other relevant topics become
available, KDIGO will consider developing a clinical practice
guidelines based on a systematic evidence review.
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